What are the commercialization strategies for RYTELO in the EU, with launch expected in 2026?

Geron Corporation is actively preparing for the commercialization of RYTELO (imetelstat) in select European Union (EU) countries, with a launch anticipated to commence in 2026. RYTELO, a first-in-class telomerase inhibitor, recently received marketing authorization from the European Commission (EC) as a monotherapy for adult patients with transfusion-dependent anemia due to very low, low, or intermediate-risk myelodysplastic syndromes (LR-MDS) who have not responded to or are ineligible for erythropoietin-based therapy. This approval followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in December 2024.

Key aspects of Geron's commercialization strategy in the EU include:

• Targeted Launch: The company plans to commercialize RYTELO in "select EU countries" starting in 2026.
• Increased Investment: Geron intends to make increased commercial investments to enhance uptake among a wider range of prescribers and stimulate long-term demand for the product.
• Medical Affairs Expansion: Efforts are underway to expand medical affairs activities, aiming to boost awareness and education regarding RYTELO.
• Maximizing Opportunity: The overarching goal is to maximize the commercial opportunity presented by RYTELO in the European market.

RYTELO's indication in the EU specifically targets adult patients with transfusion-dependent anemia caused by very low, low, or intermediate-risk myelodysplastic syndromes, provided they do not have an isolated deletion 5q cytogenetic abnormality and have had an unsatisfactory response to, or are ineligible for, erythropoietin-based therapy.

Which EU countries will it launch in?